Evidence map›Paper›PMID 38324679›Full record

ArticleScience advances2024

Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells.

Junke Wang, Jessica Gai, Tengyi Zhang, Nan Niu, Hanfei Qi, Dwayne L Thomas, Keyu Li, Tao Xia, Christina Rodriguez, Rose Parkinson and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
12.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 2 countries.

Junke WangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-8605-3087
Jessica GaiDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Tengyi ZhangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Nan NiuDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-2360-2384
Hanfei QiDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-0072-5752
Dwayne L ThomasDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0003-2069-310X
Keyu LiDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-4547-4918
Tao XiaDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Christina RodriguezDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Rose ParkinsonDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0009-0003-4960-0402
Jennifer DurhamDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0001-9097-9125
Thomas McPhaulDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Amol K NarangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Robert A AndersThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-2363-9072
Arsen OsipovDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-9000-7040
Hao WangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Jin HeDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0001-9149-2247
Daniel A LaheruDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0001-6646-0200
Joseph M HermanDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Valerie LeeDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Elizabeth M JaffeeDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0003-3841-6549
Elizabeth D ThompsonDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0003-4633-843X
Qingfeng ZhuDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0001-7871-3359
Lei ZhengDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0003-4163-2541
Bloomberg (United States) · USJohns Hopkins University · USCedars-Sinai Medical Center · USNorthwell Health · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI THOMPSON, ELIZABETH D · 1993 to 2022
$54.6M
Interrogate the interaction between tumor cells and nerves in the tumor microenvironment of pancreatic cancerR01CA169702 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ZHENG, LEI · 2013 to 2023
$3.6M
Targeting the Stroma for Pancreatic Cancer TreatmentK08CA259456 · NCI · CEDARS-SINAI MEDICAL CENTER · PI OSIPOV, ARSEN · 2021 to 2025
$1.2M
NCI NIH HHS K08 CA259456NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA169702
6 · The paper itself

Abstract

Radiotherapy is hypothesized to have an immune-modulating effect on the tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) to sensitize it to anti-PD-1 antibody (a-PD-1) treatment. We collected paired pre- and posttreatment specimens from a clinical trial evaluating combination treatment with GVAX vaccine, a-PD-1, and stereotactic body radiation (SBRT) following chemotherapy for locally advanced PDACs (LAPC). With resected PDACs following different neoadjuvant therapies as comparisons, effector cells in PDACs were found to skew toward a more exhausted status in LAPCs following chemotherapy. The combination of GVAX/a-PD-1/SBRT drives TME to favor antitumor immune response including increased densities of GZMB

Indexed as

Neoadjuvant TherapyPancreatic NeoplasmsCD8-Positive T-LymphocytesHumansProgrammed Cell Death 1 ReceptorRadioimmunotherapyTumor MicroenvironmentProgrammed Cell Death 1 Receptor

Identifiers

PMID38324679
PMCPMC10849596
OpenAlexW4391629240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.